ELAB PMGC Holdings Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1840563 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-98.5%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin27.5%
Operating margin—
Net margin-275.7%
FCF margin-207.8%
EBITDA margin—
Returns
ROE-129.1%
ROA-18.0%
ROIC (approx.)—
Asset turnover0.07x
Leverage & solvency
Liabilities / assets15.8%
Debt / equity0.00x
Current ratio1.27x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.68x
Accruals ratio-5.8%
Payout ratio—
Capex / revenue21.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $590,084 | — |
| Cost of revenue | $404,770 | — |
| Gross profit | $185,314 | — |
| R&D expense | $147,010 | $104,654 |
| SG&A expense | $2.24M | $1.09M |
| Interest expense | $257,630 | $735,197 |
| Pretax income | -$7.75M | -$4.02M |
| Income tax | $30,972 | — |
| Net income | -$7.75M | -$6.25M |
| EPS (diluted) | — | — |
| Balance sheet | ||
| Cash & equivalents | $5.40M | $3.98M |
| Short-term investments | $572,054 | — |
| Receivables | $245,423 | $5,276 |
| Inventory | $95,098 | — |
| Current assets | $6.87M | $6.05M |
| PP&E, net | $885,520 | $1,087 |
| Goodwill | $977,774 | — |
| Intangibles | $2.89M | $2.80M |
| Total assets | $12.87M | $8.99M |
| Current liabilities | $3.94M | $1.80M |
| Total liabilities | $5.03M | $2.33M |
| Shareholders' equity | $7.84M | $6.66M |
| Shares outstanding | 8,070 | 5,226 |
| Cash flow statement | ||
| Operating cash flow | -$5.93M | -$5.49M |
| Capital expenditure | $442,255 | $9,160 |
| Free cash flow | -$6.38M | -$5.50M |
| Investing cash flow | -$2.77M | -$610,564 |
| Financing cash flow | $10.12M | $6.76M |
| Depreciation & amortization | $96,145 | $546 |
| Stock-based compensation | -$19,160 | $97,167 |
Free plan shows the latest 2 periods; Pro shows all 4 🔒
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.